ADA Scientific Sessions 2025 Abstract

The Novel Dual GIP and GLP-1 Receptor Agonist Tirzepatide Attenuate Colon Cancer Development by Targeting HIF-1α Mediated Glucose Metabolism

By Yikai Zhang, Yi Fen Xie, Chao Zheng

Experiments in animalsInterventions

The paper

Yikai Zhang, Yi Fen Xie, Chao Zheng

Hangzhou

ADA Scientific Sessions 2025 Abstract, 13 Jun 2025

Presented at ADA Scientific Sessions 2025, poster 761-P

doi.org/10.2337/db25-761-p

Gut7 Oct 2026
Model estimates pancreatic cancer risk in type 2 diabetes
Cell Metabolism8 Oct 2026
A triple-target drug cut body weight by up to 19.7% in a trial
Lancet4 Oct 2026
Retatrutide reduces bodyweight in obesity and type 2 diabetes
The New England Journal of Medicine4 Oct 2026
Survodutide reduces weight in adults with diabetes and obesity